Group 1 - The core point of the article is that Zhifei Biological has recently obtained an invention patent certificate from the National Intellectual Property Administration of the People's Republic of China for a product related to GII.2 norovirus antibodies and their preparation methods and applications [1] Group 2 - Zhifei Biological's subsidiaries, Anhui Zhifei Longkema Biopharmaceutical Co., Ltd. and Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd., are also involved in this patent acquisition [1]

Core Viewpoint - The company Zhifei Biological Products (300122.SZ) has received approval from the National Medical Products Administration for clinical trials of its self-developed HK.3-JN.1 mRNA vaccine aimed at preventing diseases caused by the novel coronavirus [1] Group 1 - The vaccine is developed by the company's wholly-owned subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd [1] - The approval allows the company to initiate clinical trials for the vaccine [1]

Core Viewpoint - The company, Zhifei Biological, has received approval from the National Medical Products Administration for its subsidiary's mRNA vaccine, HK.3-JN.1, to conduct clinical trials for the prevention of COVID-19 related diseases [1] Group 1 - Zhifei Biological's subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd., is responsible for the development of the HK.3-JN.1 mRNA vaccine [1] - The approval notification number for the clinical trial is 2026LP00481 [1] - The clinical trial aims to evaluate the vaccine's effectiveness in preventing diseases caused by the novel coronavirus [1]

Core Insights - The A-share biopharmaceutical sector in 2025 is characterized by extreme polarization, with some companies experiencing profit surges while others face significant losses, indicating a harsh competitive landscape [2][3] Group 1: Profit and Loss Distribution - As of February 2, 2025, among 275 listed pharmaceutical companies that released performance forecasts, 138 are expected to be profitable while 137 are projected to incur losses, reflecting a near-even split [4] - WuXi AppTec is anticipated to lead in profitability with a projected net profit of 19.151 billion yuan, significantly outpacing its peers [5] - Conversely, Zhifei Biological is expected to report a staggering loss of 10.698 billion to 13.726 billion yuan, marking its first annual loss since going public [6] Group 2: Sector Performance Variability - The biopharmaceutical industry is witnessing a stark contrast in performance across different segments, with the medical outsourcing sector emerging as a major success story, exemplified by WuXi AppTec's projected revenue growth of 15.84% [7] - Innovative drug companies like Rongchang Biologics and Nuo Cheng Jianhua have successfully turned losses into profits, indicating a recovery in the innovative drug sector [8] - The vaccine sector, however, is facing severe challenges, with Zhifei Biological's massive losses highlighting the decline in this area [9][10] Group 3: Growth Drivers for Profitable Companies - Companies achieving growth amidst a slowing industry have focused on core products that can scale effectively, a strategy particularly evident among innovative drug firms [11] - International expansion has become essential, with companies like Nawei Technology and Kexing Pharmaceutical reporting significant revenue increases from overseas markets [13] - Effective cost control measures have also contributed to profitability, as seen in companies like Guoyao Yizhi, which closed underperforming stores to enhance overall performance [12] Group 4: Challenges Facing Innovative Drug Companies - A significant number of companies are trapped in a cycle of substantial losses, with Zhifei Biological leading the way in projected losses for 2025 [15] - Price declines have been a common issue, with at least 30 companies citing this as a reason for their losses, exacerbated by intensified competition and the implementation of national drug procurement policies [17][18] - Many small to mid-sized innovative drug companies have struggled due to a lack of differentiated innovation, leading to a failure to secure financing and resulting in cash flow issues [21] Group 5: Industry Dynamics and Future Outlook - The biopharmaceutical industry's polarization is seen as an inevitable outcome of changing core logic, with a shift from quantity to quality in drug approval processes [23][24] - The focus has shifted towards producing innovative drugs that meet unmet clinical needs rather than merely following market trends [25][26] - The year 2025 is viewed as a period of purification for the industry, eliminating "pseudo-innovation" and supporting genuine innovation, thus emphasizing the importance of creating valuable products [27]

证券代码：300122 证券简称：智飞生物 公告编号：2026-11 重庆智飞生物制品股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆智飞生物制品股份有限公司（以下简称"公司"）及全资子公司——安 徽智飞龙科马生物制药有限公司（以下简称"智飞龙科马"）、北京智飞绿竹生 物制药有限公司（以下简称"智飞绿竹"）于近日取得中华人民共和国国家知识 产权局颁发的发明专利证书。具体情况如下： | 发明专利名称 | | 专利号 | 专利证书号 | | 专利类型 | 专利申请日 | 授权公告日 | 专利权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 抗 GII.2 | 型诺如 | | | | | | | 智飞生物 | | 病毒抗体或其抗 | | ZL202511324537.8 | 第 8729835 | 号 | 发明专利 | 2025 年 09 月 | 2026 年 02 月 | 智飞绿竹 | | 原结合片段及其 | | | | | | 16 日 | ...

证券代码：300122 证券简称：智飞生物 公告编号：2026-12 重庆智飞生物制品股份有限公司 关于 HK.3-JN.1 新型冠状病毒 mRNA 疫苗 获得临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆智飞生物制品股份有限公司（以下简称"公司"）于近日收到全资子公 司安徽智飞龙科马生物制药有限公司（以下简称"智飞龙科马"）报告，由智飞 龙科马自主研发的 HK.3-JN.1 新型冠状病毒 mRNA 疫苗获得国家药品监督管理局 药物临床试验批准通知书（通知书编号：2026LP00481），同意本品开展预防新 型冠状病毒感染所致疾病的临床试验。 一、研发项目简介 新型冠状病毒感染是一种由新型冠状病毒引发的急性呼吸道传染病。新型冠 状病毒主要通过呼吸道飞沫和密切接触传播，在较封闭、不通风的空间里，该病 毒还可能借助气溶胶的形式传播。新型冠状病毒感染发病后，主要症状包括咽干、 咽痛、咳嗽和发热等，部分患者可伴有肌肉酸痛、嗅觉味觉减退或丧失、鼻塞、 流涕、腹泻、结膜炎等。老年人和免疫功能低下者感染后转为重症的风险相对较 高。 公司与中国 ...

Investment Rating - The report does not explicitly state an investment rating for the herpes zoster vaccine industry Core Insights - The herpes zoster vaccine market in China is entering an accelerated cultivation phase due to the expansion of the aging population, increased awareness of pain and complications, and improvements in the adult immunization service system [2] - The demand for herpes zoster vaccines is primarily driven by the elderly and immunocompromised populations, with the market showing long-term growth potential due to demographic changes and rising chronic disease burdens [2][4] - The competitive landscape is shifting from a focus on product efficacy and safety to a comprehensive evaluation of commercialization capabilities, including channel coverage, organizational mobilization efficiency, and service operation capabilities [2][3] Summary by Sections Overview of Herpes Zoster Disease in China - Herpes zoster is a common infectious disease in adults, with incidence risk significantly increasing with age and declining immune function [13] - The disease burden is concentrated in the elderly and immunocompromised populations, with a notable impact on quality of life due to complications such as postherpetic neuralgia [13][14] Vaccination Coverage of Herpes Zoster Vaccines in China - As of September 2024, the vaccination rate for herpes zoster among individuals aged 60 and above in China is approximately 0.79%, indicating a very low penetration stage [15] - The vaccination rate for this demographic has increased from less than 0.1% in 2022 to an estimated 0.8% in 2024, with significant regional disparities [17][18] Technology Segmentation of Herpes Zoster Vaccines in China - The herpes zoster vaccines in China are categorized into three main technological routes: live attenuated vaccines, recombinant subunit vaccines, and self-replicating RNA vaccines [20] - The market is characterized by a diverse range of products, with different technologies offering unique advantages in terms of immunogenicity, safety, and cost [5][20] Policy Landscape of the Herpes Zoster Vaccine Industry in China - The regulatory framework for herpes zoster vaccines is based on non-mandatory adult vaccine supervision, promoting accessibility and penetration through local projects and payment tools [27] - Recent policies aim to enhance the quality and safety of vaccination services, standardizing processes and improving public trust in adult immunization [27] Value Chain and Supply System of Herpes Zoster Vaccines - The value chain includes upstream raw material supply, midstream vaccine production, and downstream vaccination services, with a focus on improving efficiency across the entire chain [30][33] - The domestic supply of key raw materials is increasing, with local manufacturers enhancing their capabilities and reducing costs, thereby improving the overall competitiveness of the industry [40][46] Future Growth Drivers of the Herpes Zoster Vaccine Industry - The growth of the herpes zoster vaccine market will be driven by the diversification of technological platforms, improving coverage and accessibility [29] - The industry's ability to convert low-penetration populations into new vaccination opportunities will be crucial for future growth [3]

Core Viewpoint - The A-share pharmaceutical and biotechnology industry has over 500 listed companies, with approximately 274 having disclosed their 2025 performance forecasts, indicating a generally positive outlook for the sector [1]. Group 1: Performance Forecasts - Among the 274 companies that disclosed forecasts, 90 companies are expected to have positive performance, including profit increases, slight increases, turnaround from losses, and continued profitability [1]. - 137 companies are projected to be profitable in 2025, representing 50% of those that disclosed forecasts, with 10 companies expected to achieve a net profit exceeding 1 billion yuan [1]. Group 2: Companies with Significant Profit Forecasts - The companies expected to report net profits exceeding 1 billion yuan include WuXi AppTec, 3SBio, and Jilin Aodong, all of which forecast profit increases [4][5]. - WuXi AppTec anticipates a revenue of approximately 45.456 billion yuan for 2025, a year-on-year increase of about 15.84%, with an adjusted net profit forecast of 14.957 billion yuan, reflecting a growth of approximately 41.33% [7]. - 3SBio expects a revenue of around 4.2 billion yuan, a significant increase of approximately 251.76%, and a net profit of about 2.9 billion yuan, marking a growth of approximately 311.35% due to a key collaboration with Pfizer [9]. Group 3: Companies with Loss Forecasts - A total of 137 companies are expected to report losses in 2025, with the top three companies projected to incur losses exceeding 1 billion yuan each, including Zhifei Biological Products, Zhenbao Island, and Baile Tianheng [11]. - Zhifei Biological Products forecasts a net loss between 10.698 billion yuan and 13.726 billion yuan, primarily due to underperformance in sales and inventory impairment [15]. - Zhenbao Island anticipates a net loss of 1.012 billion yuan to 1.173 billion yuan, impacted by policy adjustments and increased cost control measures in the pharmaceutical industry [15].

Group 1 - The company is enhancing its business capabilities in diabetes GLP-1, weight loss drug semaglutide, and rare cancer diseases, indicating potential competitiveness against global pharmaceutical giants for overseas market expansion [1] - The company is actively pursuing international registration and certification for its proprietary products, aiming to address unmet clinical needs with innovative offerings, thereby improving the accessibility and affordability of vaccines and therapeutic products [1] - The company encourages stakeholders to monitor its regular reports for updates on overseas sales revenue [1]

Core Viewpoint - The company is advancing its clinical research with a focus on innovative therapies for bladder cancer and EBV-related malignancies [2] Group 1: Product Development - The company is in Phase III clinical trials for a therapeutic Bacillus Calmette-Guérin (BCG) vaccine aimed at treating non-muscle invasive bladder cancer and preventing recurrence after transurethral resection of Ta or T1 stage bladder papilloma [2] - The company is also conducting preclinical research on an EBV vaccine intended to prevent malignancies associated with Epstein-Barr virus [2] - Ongoing product development updates will be disclosed through the company's information channels [2]